Sbir phase i: motion artifact management for accurate and continuous non-invasive blood pressure monitoring

Ended Project Grant Awarded Last action

Award ID
2151591
Recipient
Awarding agency
Obligated
$256,000

Award facts

Assistance listing
47.041 Engineering
Completion date
Place of performance
Needham Heights, MA 02494, USA

Award details come from USAspending.gov.

About this award

Dynocardia Inc. received a $256,000 National Science Foundation Project Grant to advance development of a novel continuous, cuffless blood pressure monitoring device. Funded through the NSF Engineering Directorate's SBIR program, the award will support Dynocardia's efforts to address motion artifacts and enable accurate, beat-to-beat blood pressure measurements in hospital intensive care and operating room settings. Accurate 24-hour blood pressure monitoring has potential to significantly improve patient outcomes for hypertension and other chronic conditions. If successful, Dynocardia's technology could ultimately enable widespread availability of continuous blood pressure monitoring and deeper clinical insights beyond current point-in-time cuff-based measurements. The one-year project period extends from March 1, 2022 to February 28, 2023.

Description

Abstract
The broader impact/commercial potential of this small business innovation research (sbir) phase i project is to enable accurate, continuous, and widely available blood pressure (BP) measurements. The current standard of care is single point-in-time BP monitoring using an arm-cuff device. This method has two basic drawbacks: inaccuracy and the inability to measure BP continuously over 24 hours, limiting clinical insight. The major challenge to continuous reliable BP measurements is motion artifacts due to movement, such as an arm gestures. This project will advance development of a novel device for non-invasive beat-to-beat BP measurement in a cuff-less, wrist-wearable device. Accurate 24-hour BP measurement at home and other settings will significantly improve outcomes for 1.5 billion people globally who suffer from chronic high BP or hypertension, a leading cause of stroke and heart attacks. Other chronic conditions benefiting from accurate 24-hour BP measurement include sleep apnea, heart and renal failure, and dementia. This small business innovation research (sbir) phase i project utilizes a highly sensitive optomechanical sensor to capture video images of skin displacement over the radial artery to independently measure systolic and diastolic BP continuously. The technology measures BP accurately and continuously in stationary conditions (i.e., seated or lying down). The goal of this project is to identify, characterize and address motion artifacts that occur during routine use in hospital intensive care units and operating rooms. This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the foundation's intellectual merit and broader impacts review criteria.

Quick answers

Who received award 2151591?

2151591 was awarded to Dynocardia, Inc. by Division of Industrial Innovation (National Science Foundation) on March 1, 2022.

How much is award 2151591 worth?

$256,000 has been obligated on 2151591.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award